<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00073931</url>
  </required_header>
  <id_info>
    <org_study_id>1366.00</org_study_id>
    <secondary_id>CDR0000341125</secondary_id>
    <nct_id>NCT00073931</nct_id>
  </id_info>
  <brief_title>Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase II Trial Evaluating: Radioiodinated Anti-B1 (Anti-CD20) Antibody With Autologous Stem Cell Transplantation For Relapsed Or Refractory Non-Hodgkin's Lymphoma In Patients 60 Years Of Age And Older</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 tositumomab, can locate&#xD;
      cancer cells and deliver radioactive cancer-killing substances to them without harming normal&#xD;
      cells. Combining a radiolabeled monoclonal antibody with autologous stem cell transplantation&#xD;
      may be an effective treatment for non-Hodgkin's lymphoma.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining iodine I 131 tositumomab with&#xD;
      autologous stem cell transplantation in treating older patients who have relapsed or&#xD;
      refractory non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the progression-free survival of older patients with relapsed or refractory&#xD;
           non-Hodgkin's lymphoma treated with iodine I 131 tositumomab followed by autologous stem&#xD;
           cell transplantation.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the overall survival of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the toxicity and tolerability of this regimen in these patients.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
        -  Radioimmunotherapy: Patients receive a test dose of iodine I 131 tositumomab on day -24&#xD;
           to determine biodistribution. Patients then receive therapeutic iodine I 131 tositumomab&#xD;
           IV over 1 hour on day -14 and are entered into radiation isolation until day -4.&#xD;
&#xD;
        -  Autologous stem cell transplantation: Patients undergo autologous bone marrow or&#xD;
           peripheral blood stem cell transplantation on day 0. Patients undergoing bone marrow&#xD;
           transplantation receive filgrastim (G-CSF) or sargramostim (GM-CSF) subcutaneously&#xD;
           beginning on day 0 and continuing until blood counts recover.&#xD;
&#xD;
      Patients are followed at 1, 3, 6, and 12 months and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 24-30 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1999</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival measured continuously</measure>
    <time_frame>from date of transplant through date of death</time_frame>
  </primary_outcome>
  <enrollment type="Actual">25</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>5 µg/kg/day subcutaneously</description>
    <other_name>G-CSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
    <description>250µg/m2/d subcutaneously</description>
    <other_name>GM-CSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous bone marrow transplantation</intervention_name>
    <description>autologous stem cells given via central catheter</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>autologous stem cells given via central catheter</description>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>tositumomab and iodine I 131 tositumomab</intervention_name>
    <description>given intravenously (test dose of 1.7-10 mg/kg tositumomab antibody radiolabeled with ~10 mCi I-131) or via central catheter (therapy dose of 1.7-10 mg/kg tositumomab radiolabeled with individually calculated therapy dose of I-131)</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed non-Hodgkin's lymphoma&#xD;
&#xD;
          -  CD20+ disease&#xD;
&#xD;
          -  Failed at least 1 prior standard systemic therapy&#xD;
&#xD;
          -  Persistent lymphoma by physical examination, radiographic studies, bone marrow&#xD;
             evaluations, flow cytometry, or polymerase chain reaction&#xD;
&#xD;
          -  Tumor burden less than 500 cc by computed tomography or MRI&#xD;
&#xD;
               -  No splenomegaly&#xD;
&#xD;
          -  Autologous hematopoietic stem cells or bone marrow harvested and cryopreserved&#xD;
&#xD;
               -  No circulating lymphoma cells by morphology or flow cytometry at or near the time&#xD;
                  of peripheral blood stem cell (PBSC) collection if unpurged PBSCs are to be used&#xD;
&#xD;
               -  10% or less marrow involvement by flow cytometry or morphology if purged bone&#xD;
                  marrow is to be used&#xD;
&#xD;
          -  No CNS lymphoma&#xD;
&#xD;
          -  No chronic lymphocytic leukemia or small lymphocytic lymphoma/well-differentiated&#xD;
             lymphocytic lymphoma&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  60 to 80&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  SWOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 60 days&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin less than 1.5 mg/dL&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine less than 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No active coronary artery disease&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  FEV_1 at least 70% of expected&#xD;
&#xD;
          -  Vital capacity at least 70% of expected&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Able to perform self-care during radiation isolation&#xD;
&#xD;
          -  No major organ dysfunction&#xD;
&#xD;
          -  No major infection&#xD;
&#xD;
          -  No circulating anti-mouse antibody&#xD;
&#xD;
          -  No other serious medical condition considered to represent contraindications to bone&#xD;
             marrow transplantation&#xD;
&#xD;
          -  No competing causes of death that would predict life span to be less than 10&#xD;
             additional years&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior bone marrow or stem cell transplantation&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy greater than 20 Gy to any critical normal organ (e.g., lung,&#xD;
             liver, spinal cord, or more than 25% of red marrow)&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 30 days since prior systemic antilymphoma therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ajay K. Gopal, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Gopal AK, Rajendran JG, Gooley TA, Pagel JM, Fisher DR, Petersdorf SH, Maloney DG, Eary JF, Appelbaum FR, Press OW. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults &gt; or = 60 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol. 2007 Apr 10;25(11):1396-402. Epub 2007 Feb 20.</citation>
    <PMID>17312330</PMID>
  </results_reference>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>December 10, 2003</study_first_submitted>
  <study_first_submitted_qc>December 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2003</study_first_posted>
  <last_update_submitted>February 3, 2015</last_update_submitted>
  <last_update_submitted_qc>February 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2015</last_update_posted>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tositumomab I-131</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

